These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38453822)

  • 21. Toceranib phosphate in the treatment of canine thyroid carcinoma: 42 cases (2009-2018).
    Sheppard-Olivares S; Bello NM; Wood E; Szivek A; Biller B; Hocker S; Wouda RM
    Vet Comp Oncol; 2020 Dec; 18(4):519-527. PubMed ID: 32012432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of advanced-stage canine nasal carcinomas with toceranib phosphate: 23 cases (2015-2020).
    Merino-Gutierrez V; Borrego JF; Puig J; Hernández A; Clemente-Vicario F
    J Small Anim Pract; 2021 Oct; 62(10):881-885. PubMed ID: 34131916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma.
    Gardner HL; London CA; Portela RA; Nguyen S; Rosenberg MP; Klein MK; Clifford C; Thamm DH; Vail DM; Bergman P; Crawford-Jakubiak M; Henry C; Locke J; Garrett LD
    BMC Vet Res; 2015 Jun; 11():131. PubMed ID: 26062540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study.
    Pellin MA; Wouda RM; Robinson K; Tsimbas K; Kurzman ID; Biller BJ; Vail DM
    Vet Comp Oncol; 2017 Sep; 15(3):919-931. PubMed ID: 27146577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study.
    Chon E; McCartan L; Kubicek LN; Vail DM
    Vet Comp Oncol; 2012 Sep; 10(3):184-93. PubMed ID: 22235941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of the efficacy of firocoxib (Previcox®) and grapiprant (Galliprant®) in an induced model of acute arthritis in dogs.
    de Salazar Alcalá AG; Gioda L; Dehman A; Beugnet F
    BMC Vet Res; 2019 Aug; 15(1):309. PubMed ID: 31464629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
    London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
    Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs.
    Yamazaki H; Miura N; Lai YC; Takahashi M; Goto-Koshino Y; Yasuyuki M; Nakaichi M; Tsujimoto H; Setoguchi A; Endo Y
    J Vet Med Sci; 2017 Jul; 79(7):1225-1229. PubMed ID: 28592719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toceranib phosphate-associated nephrotic syndrome in a dog: a case report.
    Remerowski SM; Herrera CL; Donnelly LL
    BMC Vet Res; 2021 Apr; 17(1):146. PubMed ID: 33827545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retrospective evaluation of toceranib (Palladia) treatment for canine metastatic appendicular osteosarcoma.
    Kim C; Matsuyama A; Mutsaers AJ; Woods JP
    Can Vet J; 2017 Oct; 58(10):1059-1064. PubMed ID: 28966355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective, multi-centre, Veterinary Radiation Therapy Oncology Group study reveals potential efficacy of toceranib phosphate (Palladia) as a primary or adjuvant agent in the treatment of canine nasal carcinoma.
    Ehling TJ; Klein MK; Smith L; Prescott D; Haney S; Looper J; LaDue T; Brawner W; Fidel J; Shiomitsu K; Green E; Saba C; Turek M; Farrelly J
    Vet Comp Oncol; 2022 Mar; 20(1):293-303. PubMed ID: 34655275
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toceranib phosphate and firocoxib-mediated partial response in a dog with advanced intranasal sarcoma.
    Osada H; Okazawa T; Kushida K; Kishimoto M; Ikeda M; Kondo H; Kimura J; Ohmori K
    J Vet Med Sci; 2023 Sep; 85(9):1004-1009. PubMed ID: 37532540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study.
    Robat C; London C; Bunting L; McCartan L; Stingle N; Selting K; Kurzman I; Vail DM
    Vet Comp Oncol; 2012 Sep; 10(3):174-83. PubMed ID: 22235914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
    Yancey MF; Merritt DA; Lesman SP; Boucher JF; Michels GM
    J Vet Pharmacol Ther; 2010 Apr; 33(2):162-71. PubMed ID: 20444041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized trial of cisplatin versus firocoxib versus cisplatin/firocoxib in dogs with transitional cell carcinoma of the urinary bladder.
    Knapp DW; Henry CJ; Widmer WR; Tan KM; Moore GE; Ramos-Vara JA; Lucroy MD; Greenberg CB; Greene SN; Abbo AH; Hanson PD; Alva R; Bonney PL
    J Vet Intern Med; 2013; 27(1):126-33. PubMed ID: 23205923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful management of lymphangiosarcoma in a puppy using a tyrosine kinase inhibitor.
    Kim JH; Yoon H; Yoon HY; Eom K; Sung HJ; Kim JH
    Can Vet J; 2018 Apr; 59(4):367-372. PubMed ID: 29606721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia.
    Berger EP; Johannes CM; Post GS; Rothchild G; Shiu KB; Wetzel S; Fox LE
    J Feline Med Surg; 2018 Feb; 20(2):95-102. PubMed ID: 29172873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of carboplatin and toceranib phosphate on serum vascular endothelial growth factor (VEGF) and metalloproteinase-9 (MMP-9) levels and survival in canine osteosarcoma.
    Gieger TL; Nettifee-Osborne J; Hallman B; Johannes C; Clarke D; Nolan MW; Williams LE
    Can J Vet Res; 2017 Jul; 81(3):199-205. PubMed ID: 28725110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response and outcome following toceranib phosphate treatment for stage four anal sac apocrine gland adenocarcinoma in dogs: 15 cases (2013-2017).
    Elliott JW
    J Am Vet Med Assoc; 2019 Apr; 254(8):960-966. PubMed ID: 30938616
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolerance of firocoxib in dogs with osteoarthritis during 90 days.
    Lecoindre O; Pepin-Richard C
    J Vet Pharmacol Ther; 2011 Apr; 34(2):190-2. PubMed ID: 21395612
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.